Targeting the DNA Damage Response for Anti-Cancer Therapy
Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely
- PDF / 9,180,744 Bytes
- 402 Pages / 439.42 x 683.15 pts Page_size
- 27 Downloads / 196 Views
John Pollard · Nicola Curtin Editors
Targeting the DNA Damage Response for Anti-Cancer Therapy
Cancer Drug Discovery and Development
Series Editor Beverly A. Teicher Bethesda, MD, USA
More information about this series at http://www.springer.com/series/7625
John Pollard • Nicola Curtin Editors
Targeting the DNA Damage Response for Anti-Cancer Therapy
Editors John Pollard Vertex Pharmaceuticals (Europe) Ltd Abingdon, Oxfordshire, UK
Nicola Curtin Northern Institute for Cancer Research Medical School Newcastle University Newcastle upon Tyne, UK Newcastle University Institute for Ageing Medical School Newcastle University Newcastle upon Tyne, UK
ISSN 2196-9906 ISSN 2196-9914 (electronic) Cancer Drug Discovery and Development ISBN 978-3-319-75834-3 ISBN 978-3-319-75836-7 (eBook) https://doi.org/10.1007/978-3-319-75836-7 Library of Congress Control Number: 2018936509 © Springer International Publishing AG, part of Springer Nature 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Humana Press imprint is published by the registered company Springer International Publishing AG part of Springer Nature. The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Contents
1 Targeting DNA Repair in Anti-Cancer Treatments������������������������������ 1 Thomas Helleday 2 The DNA Damage Response: Roles in Cancer Etiology and Treatment������������������������������������������������������������������������������������������ 11 Laura R. Butler, Oren Gilad, and Eric J. Brown 3 Control of DNA Replication by ATR������������������������������������������������������ 35 Emilio Lecona and Oscar Fernández-Capetillo 4 Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors ���������������������������������������������������������������������������������� 63 Nicola Curti
Data Loading...
